gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GOSSHealthcarePharmaceuticals

Gossamer Bio, Inc. Common Stock (GOSS)

$9.95+7.22%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$9.95▼ 94.80% in range
Nov 3, 2025Low $8.43 · High $911.36Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Gossamer Bio closed at $9.95 on Nov 4, up 7.22%, 98.9% below its 52-week closing high. Volume of 115.9K shares was 0.54× its 20-day average (below normal).

Split-adjusted performance: -7.7% over one month, -64.5% over six months, -94.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $9.24M, down 19.6% from a year earlier, with a net margin of 182.9%.

Short interest was 1.4M shares at the Oct 15 settlement, up 16.0% from the prior report (24.9% of float, 5.1 days to cover).

Market cap$60.9M6.1M shares
Revenue · quarter$9.2M−19.6% YoY
Diluted EPS$-6.40—
P/E · TTM—P/S 1.1×
Net margin182.9%Gross 100.0%
Dividend yieldNone
52-week range8.43 – 911.36−98.9% from high
Volume115.9K0.54× 20-day avg
Volatility · 60d1,266.0%Annualised
Short % of float24.9%5.1 days to cover
Net cash$20.9MCash $57.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.9%1M −7.7%3M −30.3%6M −64.5%YTD −96.0%1Y −94.8%3Y −75.0%5Y −99.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum16
Revenue growth30
Net margin99
Value (low P/E)—
Size35

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.4M+16.0% vs prior
Days to cover5.1Settled Oct 15
% of float24.9%
Short vol. 10d57.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GOSSGossamer Bio$9.95+7.22%−64.5%−19.6%182.9%—$60.9M
XBITXBiotech$1.95−2.01%−23.5%———$59.5MCompare
SPROSpero Therapeutics$1.07+2.88%−57.7%−100.0%—8.4$62.3MCompare
VRCAVerrica Pharmaceuticals$3.46+5.02%−59.0%−53.8%−224.4%—$59.4MCompare
QUCYQuantum Cyber N.V$0.7430+2.65%————$62.5MCompare
RNXTRenovoRx$1.31+1.55%+47.2%+115.4%−320.2%—$59.1MCompare
CLNNClene$4.10+8.75%−42.7%+233.3%−14915.6%—$58.3MCompare
NMADNomad Power Solutions$3.60+2.27%————$58.0MCompare
CTORCitius Oncology$0.5470−0.55%−39.8%—−597.4%—$57.9MCompare

News about Gossamer Bio

All news →
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc. · May 31, 2026▼ NegativeGOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSSGlobeNewswire Inc. · May 31, 2026▼ NegativeGOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSSGlobeNewswire Inc. · May 30, 2026▼ NegativeGossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSSGlobeNewswire Inc. · May 29, 2026▼ NegativeGOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1stGlobeNewswire Inc. · May 29, 2026▼ Negative

Quick answers

What does Gossamer Bio do?
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology.
What is GOSS's market cap?
$60.86M, based on the Nov 4 close of $9.95.
Does Gossamer Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GOSS is sold short?
1.4M shares, 24.9% of float, as of Oct 15, 2026.
What sector is GOSS in?
Healthcare, in the Pharmaceuticals industry.

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

HQ: San Diego, CA162 employeesListed Feb 8, 2019gossamerbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology